In this context, MGD-C9 displayed remarkable synergistic effects when combined with BTK inhibitor (pirtobrutinib) and IDH1 inhibitor (ivosidenib) in multiple MM and AML, and DLBCL cells. This evidence concerns the gene BTK and acute myeloid leukemia.